Want to see CCM full AI Analyst Report?
Concord Medical Services (CCM) AI Stock Analysis
Concord Medical Services
(NYSE:CCM)
The score is primarily held down by weak financial fundamentals—ongoing losses, continued cash burn, and high leverage with negative equity. Technicals also remain bearish with the stock below major moving averages and negative MACD, while valuation is unfavorable due to a negative P/E and no dividend support.
Concord Medical Services (CCM) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $519.56K
- Dividend Yield
- ―
- Average Volume (3M)
- 44.91K
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- 0.75
- Revenue Growth
- 20.26%
- EPS Growth
- 69.68%
- Country
- US
- Employees
- 610
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Care Facilities
Concord Medical Services Business Overview & Revenue Model
Company Description
Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People’s Republic of China. It operates in two segments, Network and Hospital. The company’s services includ...
How the Company Makes Money
CCM makes money primarily by delivering and managing oncology-focused clinical services, with revenues historically tied to patient volumes and the utilization of high-end equipment used in cancer diagnosis and treatment. Key revenue streams include:...
Concord Medical Services Financial Statement Overview
Summary
Despite a strong 2025 revenue rebound (+25.9% YoY) and smaller losses versus 2024, the company still shows persistent operating/net losses, consistently negative operating cash flow and free cash flow, and a highly stressed capital structure with very high debt (~3.6B) and deeply negative equity (~-2.1B). Overall improvement is off a weak base, but financial risk remains elevated.
Income Statement
18Very NegativeBalance Sheet
12Very NegativeCash Flow
15Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 585.66M | 460.51M | 383.96M | 537.40M | 472.08M | 485.63M |
| Gross Profit | 40.31M | 25.82M | -79.16M | -76.61M | -152.41M | -56.90M |
| EBITDA | -75.84M | -71.77M | -345.62M | -334.53M | -392.23M | -354.24M |
| Net Income | -124.44M | -92.81M | -308.24M | -297.66M | -489.66M | -271.43M |
Balance Sheet | ||||||
| Total Assets | 6.55B | 6.55B | 6.73B | 6.05B | 6.00B | 6.23B |
| Cash, Cash Equivalents and Short-Term Investments | 297.79M | 297.79M | 350.85M | 58.14M | 158.28M | 157.39M |
| Total Debt | 3.63B | 3.63B | 3.93B | 3.30B | 3.24B | 2.73B |
| Total Liabilities | 4.70B | 4.70B | 5.11B | 4.31B | 3.99B | 3.49B |
| Stockholders Equity | -2.10B | -2.10B | -2.28B | -2.12B | -1.86B | -1.37B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -293.16M | -808.58M | -392.17M | -600.47M | -1.12B |
| Operating Cash Flow | 0 | -201.82M | -397.75M | -276.47M | -216.69M | -359.31M |
| Investing Cash Flow | 0 | 53.97M | -593.44M | -47.68M | -118.79M | -565.98M |
| Financing Cash Flow | 0 | 197.23M | 1.15B | 257.65M | 383.09M | 642.45M |
Concord Medical Services Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCM, the sentiment is Neutral. The current price of 3.60 is below the 20-day moving average (MA) of 3.67, below the 50-day MA of 3.85, and below the 200-day MA of 4.21, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 52.49 is Neutral, neither overbought nor oversold. The STOCH value of 29.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CCM.
Concord Medical Services Risk Analysis
Concord Medical Services disclosed 78 risk factors in its most recent earnings report. Concord Medical Services reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
2 New RisksConcord Medical Services Peers Comparison
Overall Rating
JYNT60Neutral
AMS56Neutral
CCEL52Neutral
PIII48Neutral
DCGO41Neutral- CCM40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JYNT | 60Neutral | $99.43M | 27.59 | 22.00% | ― | -17.84% | ― |
| AMS | 56Neutral | $8.45M | -4.95 | -7.45% | ― | 3.97% | 28.88% |
| CCEL | 52Neutral | $42.01M | -23.86 | 15.84% | ― | -1.96% | -314.41% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| PIII | 48Neutral | $29.68M | -0.12 | 160.54% | ― | 2.81% | 26.63% |
| DCGO | 41Neutral | $24.44M | -0.11 | -115.58% | ― | -32.40% | -969.05% |
| CCM | 40Underperform | $15.50M | -0.03 | 5.16% | ― | 20.26% | 69.68% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CCM | Concord Medical Services | 3.59 | -2.09 | -36.80% | |
| AMS | American Shared Hospital Services | 1.25 | -0.87 | -41.04% | |
| JYNT | Joint Corp | 7.32 | -0.97 | -11.70% | |
| CCEL | Cryo-Cell International | 5.35 | 0.97 | 22.09% | |
| DCGO | DocGo, Inc. | 0.21 | -0.87 | -80.19% | |
| PIII | P3 Health Partners Inc. | 4.00 | -4.41 | -52.45% |
Concord Medical Services Corporate Events
Concord Medical Names Interim CFO as Wei Jiang Steps Down
Concord Medical announced that chief financial officer Wei Jiang stepped down from his role effective June 30, 2026, to concentrate on the business and operations of Concord Healthcare Group, the company’s Hong Kong-listed subsidiary. The compa...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 18, 2026